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Abstract Patient-derived xenograft (PDX) models of a grow-
ing spectrum of cancers are rapidly supplanting long-
established traditional cell lines as preferred models for
conducting basic and translational preclinical research. In
breast cancer, to complement the now curated collection of
approximately 45 long-established human breast cancer cell
lines, a newly formed consortium of academic laboratories,
currently from Europe, Australia, and North America, herein
summarizes data on over 500 stably transplantable PDX
models representing all three clinical subtypes of breast cancer
(ER+, HER2+, and BTriple-negative^ (TNBC)). Many of
these models are well-characterized with respect to genomic,
transcriptomic, and proteomic features, metastatic behavior,
and treatment response to a variety of standard-of-care and
experimental therapeutics. These stably transplantable PDX
lines are generally available for dissemination to laboratories
conducting translational research, and contact information for
each collection is provided. This review summarizes current
experiences related to PDX generation across participating
groups, efforts to develop data standards for annotation and
dissemination of patient clinical information that does not
compromise patient privacy, efforts to develop complementa-
ry data standards for annotation of PDX characteristics and
biology, and progress toward Bcredentialing^ of PDX models
as surrogates to represent individual patients for use in pre-
clinical and co-clinical translational research. In addition, this
review highlights important unresolved questions, as well as
current limitations, that have hampered more efficient gener-
ation of PDX lines and more rapid adoption of PDX use in
translational breast cancer research.
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1 Introduction
Human breast cancer is now recognized, not as a single
disease, but as a heterogeneous collection of diseases
characterized by diversity in histology, genomic alter-
ations, gene expression, metastatic behavior, and treat-
ment responses [1–7]. In addition to heterogeneity be-
tween tumors across the patient population (or between
two primary tumors in a single patient), recent data have
also demonstrated considerable intra-tumoral heterogene-
ity (that is, between cells within a single tumor and be-
tween a primary tumor and its associated metastases in a
single patient). This degree of heterogeneity is a signifi-
cant hindrance for making effective treatment decisions
and begs for the development of personalized approaches
to therapy based on the specific biology of an individual
and their unique tumor [8]. With respect to basic and
translational research, the existence of disease heterogene-
ity, both within and among breast cancers, also presents
significant challenges to generation and use of relevant
preclinical models that represent the full spectrum of
breast disease [9, 10].
If our ultimate goal is to offer each breast cancer patient an
individualized treatment plan tailored to her (or his) specific
tumor and progression status, it will be essential to define fully
the molecular and cellular heterogeneity within and among the
tumor subtypes, and indeed within each patient’s tumor, and
relate these differences to clinical behavior. Specifically, these
characteristics need to be linked to metastatic behavior and
differential treatment response, the lethal aspects of breast
cancer, in order to Bpersonalize^ effective treatment. Patient-
derived xenograft (PDX) models hold high promise as a dis-
covery and validation platform, particularly as a unified col-
lection across multiple institutions, for meeting this daunting
challenge.
1.1 The problem of inter-tumoral heterogeneity
Clinically, breast cancers are divided essentially into three
subtypes: (1) those that express the estrogen receptor alpha
(ER+) (which typically also express the progesterone receptor
(PR+)), (2) those that are genomically amplified for and/or
overexpress ERBB2 (HER2+) (encoding a member of the epi-
dermal growth factor receptor family of tyrosine kinases), and
(3) those that express none of these three markers (termed
Btriple negative^ breast cancer (TNBC)) [1–4].While clinical-
ly useful, molecularly targeted therapies exist for ER+ breast
cancer (e.g., selective estrogen receptor modulators (SERMs),
aromatase inhibitors (AIs), selective estrogen receptor
downregulators (SERDs)) [11] and HER2+ breast cancer
(e.g., trastuzumab, lapatinib) [12], there are currently no ap-
proved targeted therapies for TNBC. Current treatment of
TNBC entails surgery coupled with radiotherapy and/or che-
motherapy (most often taxane- or anthracycline-based, with
platinum-based agents emerging as promising first-line thera-
pies (e.g., [13])) in either the neoadjuvant (before surgery) or
adjuvant (after surgery) settings.
With the development of RNA expression array technology
over 15 years ago, more detailed molecular classification of
breast cancer became possible. In a landmark analysis of global
RNA expression, five intrinsic molecular subtypes of breast can-
cer were proposed: luminal A (ER+, with signatures consistent
with lower proliferation rates that can be correlated with compar-
atively lower Ki67 immunostaining), luminal B (ER+, with sig-
natures consistent with elevated proliferation that can be corre-
lated with comparatively higher Ki67 immunostaining), basal-
like (predominantly TNBC), HER2-enriched, and normal breast-
like. Each molecular subtype correlated with unique clinical be-
havior including differences in overall survival, patterns of me-
tastasis, and response to treatment [4–7]. Subsequently, the
claudin-low subtype was identified. Claudin-low tumors are pre-
dominantly TNBC, with comparatively low expression of
claudins 3, 4, and 7 [14], enrichment for mesenchymal markers
[5], and enrichment of a stem cell-like (CD44+/CD24Neg/Low)
gene expression signature [5, 15, 16].
Within the last 5 years, detailed genomic analyses of breast
cancers by several groups including the ICGC, TCGA, and
METABRIC consortia [17–21] have shown that additional
molecular subtypes associated with distinct survival trends
can be distinguished, such as the 4% of breast cancers that
are ER+ with complex amplifications around 11q [18] and
those showing differential survival associated with PIK3CA
mutation [22, 23]. TNBC has been found to constitute at least
two and perhaps more, distinct biological subgroups based on
integrated genomics [24]—a genomically quiescent, PIK3CA
mutation-containing, intermediate-good prognosis group
(about 25% of TNBC) that groups more with ER+ cancers
(a proportion express AR) of the IntClust4 subtype and the
remainder which are almost universally mutated for TP53 and
have unstable genomes, a basal epithelial gene expression
signature type, and poor prognosis with early relapse. Some
TNBC gene expression studies have suggested TNBC could
be subdivided further into four or more distinct subgroups
[25–28].
1.2 The problem of intra-tumoral heterogeneity
Pathologists have long appreciated heterogeneity in both his-
tology and biomarker expression within a given tumor. For
example, in ER+ tumors, not all cells express the receptor.
Clinically, ER+ breast cancers can be qualified as such even
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if only 1% of cells express detectable levels of ER protein,
though some low-expressing tumors may behave as ER-
negative tumors in response to targeted therapies [29, 30].
Similarly, HER2+ tumors can show regional variation in ex-
pression by immunohistochemistry and copy number per cell
by fluorescence in situ hybridization, with positivity clinically
defined as 10% of cells positive (CAP Guidelines) [12, 31,
32].
Although clonal structure has been appreciated as a defin-
ing feature of cancers for several decades [33], methods for
understanding clonal structure in solid epithelial cancers have
only recently advanced. Until very recently, the existence of
genetically distinct subpopulations within tumors, and within
metastatic cell populations, was not appreciated (see [34–36]
and references therein). With the development of computa-
tional approaches to infer clonal structure from bulk tumor
sequence data (e.g., [20, 37–41]), as well as methods for
single-cell DNA and RNA sequencing (e.g., [42–48]), breast
cancers are now known to contain multiple genetically distinct
subclones [49, 50]. Primary TNBCs have been shown to be
clonally diverse among patients with the same stage/grade of
tumor. Further work suggests that distinct subclones may, in
some instances, be capable of interacting with one another to
maintain homeostatic balance between clonal populations and
promote tumor growth [51].
1.3 Patient-derived breast cancer xenografts as potentially
powerful tools for preclinical and translational research
In theory, if PDX models can represent the full spectrum of
heterogeneity of breast cancers in the population and can be
fully Bcredentialed^ to retain the critical molecular and bio-
logical properties of their tumor of origin, these models would
then represent exceptionally powerful tools for translational
research. In large part, their potential power lies in the fact that
they have been demonstrated to be biologically stable
(generally) and, as such, are renewable indefinitely. Thus,
PDX models can be interrogated in greater depth both biolog-
ically and molecularly than any given patient sample is likely
to be (unless very large). Further, PDX can be challenged with
as many candidate therapeutics, or treatment regimens, as de-
sired in a relatively short time frame versus what can be ac-
complished in the clinic. In contrast, the tumor of origin (and
patient) can only be challenged sequentially with one treat-
ment regimen at a time and only at significant risk of poten-
tially lethal or debilitating side effects.
Herein, we garner the collective experience of a new inter-
national consortium of breast cancer PDX developers to re-
view the state of the art in the field, to outline open questions
remaining to be addressed, and to summarize the utility, lim-
itations, and future promise of breast cancer PDX models in
translational research.
2 The state of the art in breast cancer PDX modeling
2.1 Patient-derived xenograft models that represent all
three clinically defined breast cancer subtypes have been
established by various groups
In addition to the need to represent the heterogeneity of
breast cancers as completely and accurately as possible,
breast cancer is heavily influenced by the tumor microen-
vironment, making in vivo models desirable for studying
complex processes like tumor metastasis and response to
therapy. Efforts to establish stably transplantable xenograft
lines directly from patients into immunocompromised
mice have been going on for decades. Unfortunately, while
initial take rates (i.e., initial outgrowths directly from pa-
tients) can be quite high (~40–90%) [52–54], success rates
of generating stably transplantable xenografts (generally,
but not uniformly, defined as PDX with the ability to be
serially transplanted ≥3 passages in mice (variously
termed Bpassage 2 (P2),^ with P0 being the initial trans-
plant from mouse to human, or Btransplant generation 3
(TG3)^) (Tables 1 and 3) from early efforts were compar-
atively low, in the 10% range overall [52, 53, 55–64]. As a
consequence, few stably transplantable models were
established for dissemination to the research community
from this earlier work.
More recently, with newly developed immunodeficient
host mouse models [65] and modified transplantation con-
ditions, overall stable take rates have now reached in ex-
cess of 20% on a routine basis (e.g., [13, 37, 54, 66–75]).
Further, a concerted effort is being made to develop these
collections of stable, well-characterized, PDX lines as
quality-controlled, renewable tissue resources for distribu-
tion to the research community. A list of PDX collections
available for dissemination, along with the patient/tumor
population characteristics from which they were derived,
is presented in Table 1; contact information for each col-
lection is listed in Table 2. In addition to collections res-
ident in academic institutions, several commercial entities
retain PDX collections of their own, consisting of PDX
lines either generated in-house or licensed from academic
institutions. These commercial collections are not
discussed here.
Taken in aggregate, the academic institutions partici-
pating in this consortium have developed 537 individual
PDX lines, representing over 500 unique patients. With
respect to clinical subtypes represented, 56% of patients
yielding PDX lines had TNBC, with 36% of patients
having ER+ cancer. Patients with HER2+ breast cancer
are significantly underrepresented in these collections,
representing only 8% of patients yielding PDX models,
due to the combined facts that they represent only ~10–
15% of all breast cancers and show a lower overall take
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rate than TNBC (which also accounts for 10–15% of all
breast cancers, but shows a higher take rate) (Table 3).
Given the clinical observation that patients of different
ethnic and racial backgrounds can have distinct treatment
responses and disease outcomes, an important consider-
ation is the ethnic and racial distribution of patients
yielding PDX lines. In general, the diversity of PDX
lines in a given collection represents the diversity in the
associated patient population from which they were de-
rived. While Caucasian women are most heavily repre-
sented across these collections, there are now a number
of PDX lines representing African American and
Hispanic women (Table 1). However, only a few PDX
lines represent patients of Asian or African descent, and
no PDX lines represent indigenous populations (e.g.,
Native Americans), or male breast cancer patients,
among others.
Of note, the PDX lines representing Continental African
patients from Ghana (Wicha et al., unpublished) were devel-
oped using primary tumor samples that had been viably frozen
and shipped on dry ice prior to transplantation using a recently
tested cryopreservation strategy (Table 3) (Lewis et al., unpub-
lished), thus demonstrating that it should be possible to devel-
op PDX tissue resources representing patients even from re-
mote and underserved areas in the world where no active PDX
development efforts may exist.
Finally, it is critical to recognize that the collections includ-
ed in this review are exclusively from academic groups in
Europe, Australia, and North America. Going forward, it will
be important to include additional collections from other geo-
graphic regions that undoubtedly will have better representa-
tion of the patient demographics of the regions in which they
function. Researchers and clinicians interested in participating
in this International Breast Cancer Patient-Derived Xenograft
Consortium should contact the corresponding author (M.T.
Lewis) to be added to the mailing list.
3 Open questions regarding generation and use
of breast PDX models
Detailed protocols currently used for generation of patient-
derived xenograft (PDX) models of breast cancer have been
published recently by De Rose et al. and Zhang et al. [54, 72]
and will not be discussed in detail here. Similarly, the advan-
tages and limitations of PDX models relative to clinical sam-
ples and established cell lines have also been discussed in
detail elsewhere [76–79]. For the purposes of this review, we
will briefly restate and highlight some of these strengths and
limitations, but in the context of particular unresolved ques-
tions and issues currently being addressed by the breast PDX
community.
3.1 Are PDX really any better than xenografts made using
long-established cell lines?
A number of immortalized or transformed cell lines have been
established and extensively characterized over the last several
decades, notably the MCF series, the MDA series, and more
recently the SUM series (see [80–82] and references therein).
Table 2 Contact information for PDX collections
Academic institution Contact name and e-mail
Baylor College of
Medicine (USA)
Michael Lewis
(mtlewis@bcm.edu)
Lacey Dobrolecki
(dobrolec@bcm.edu)
Bellvitge Institute for
Biomedical Research
(Spain)
Eva Gonzalez-Suarez
(egsuarez@idibell.cat)
British Columbia Cancer
Agency (Canada)
Samuel Aparicio
(saparicio@bccrc.ca)
Ecole Polytechnique
Federale De Lausanne
(Switzerland)
Cathrin Brisken
(cathrin.brisken@epfl.ch)
Institut Bergonié (France) Richard Iggo
(r.iggo@bordeaux.unicancer.fr)
Institut Curie (France) Elisabetta Marangoni
(elisabetta.marangoni@curie.fr)
The Jackson Laboratory
(JAX) (USA)
Carol Bult
(Carol.Bult@jax.org)
Susie Airhart
(Susie.Airhart@jax.org)
MD Anderson Cancer
Center (USA)—
Meric-Bernstam
Funda Meric-Bernstam
(fmeric@mdanderson.org)
MD Anderson Cancer
Center (USA)—
Piwnica-Worms
Helen Piwnica-Worms
(hpiwnica-worms@mdanderson.org)
University of Colorado
Anschutz Medical
Campus (USA)
Carol Sartorius
(Carol.Sartorius@ucdenver.edu)
Peter Kabos
(Peter.Kabos@ucdenver.edu)
University of Manchester
Institute of Cancer
Sciences (UK)
Robert Clarke
(Robert.Clarke@manchester.ac.uk)
Denis Alferez
(denis.alferez@manchester.ac.uk)
University of Michigan
(USA)
Max Wicha
(mwicha@med.umich.edu)
University of Utah—
Huntsman Cancer
Institute (USA)
Alana Welm
(Alana.Welm@hci.utah.edu)
Walter and Eliza Hall
Institute of
Medical Research
(WEHI) (Australia)
Geoffrey Lindeman
(lindeman@wehi.edu.au)
Jane Visvader
(visvader@wehi.edu.au)
Washington University
(USA)
Shunqiang Li
(shunqiangli@wustl.edu)
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Extensive efforts have been made to correlate gene expression,
genomic copy number changes, andmutationswith growth char-
acteristics and therapeutic responses [83–86]. Unfortunately,
while all of these cell lines grow in vitro under tissue culture
conditions, only a percentage of these will grow when
transplanted as cell line xenografts, and a fewer will form me-
tastases despite many of them being derived from pleural effu-
sions and ascites [87–91]. Thus, a large proportion of the studies
aimed at translational endpoints using cell lines have been con-
ducted in vitro, rather than in vivo as cell line xenografts.
It is now appreciated that gene expression patterns under
two-dimensional in vitro culture conditions can be quite dif-
ferent than expression patterns observed under three-
dimensional culture conditions, or when cell lines are grown
as xenografts in immunocompromised mice [92]. Similarly,
drug sensitivity under varied conditions can be different for a
given cell line [93]. Indeed, in transcriptome studies of clinical
samples versus established cancer cell lines, cell lines clus-
tered together regardless of the tissue of origin, rather than
clustering with the clinical samples they were intended to
model [94]. Given these differences, it is perhaps to be expect-
ed that cell line-based studies have failed to translate clinically
with high frequency and thus may not be suitable to address
many clinical questions [8, 95]. In contrast, PDX lines are, by
their nature, established and maintained in vivo and have been
shown to retain a remarkable degree of biological, histologi-
cal, genomic, transcriptomic, and biomarker fidelity with their
tumors of origin (see below).
Most established human breast cancer cell lines have been
maintained in vitro over several decades and in many different
laboratories. Long-term culture has, in several cases, been as-
sociated with extensive clonal selection and loss of heterogene-
ity [94, 96]. Further, inconsistent handling as well as both in-
advertent and deliberate selection are known to have led to
genetic drift such that a multitude of sublines of individual
parental lines now exist. As such, isolates of a given cell line
(e.g., MCF7) can vary considerably from laboratory to labora-
tory with respect to genomics and gene expression [97, 98].
Each subline can thus possess its own unique attributes (inva-
sive vs. not, metastatic vs. not, adherent vs. not, drug resistant
vs. sensitive, etc.). Further, since the tumor of origin from
which a given cell line was derived cannot be studied in most
cases, and only limited clinically relevant data were collected,
there is typically no way to evaluate what the original mutation
spectrum in the patient was or what the clinical behavior of the
tumor of origin actually were. Taken together, these shortcom-
ings limit the utility of established breast cancer cell lines for
predictive/correlative studies. However, these shortcomings do
not necessarily impinge on the use of established cell lines to
investigate basic biological mechanisms. In contrast, PDXs
show behavioral, genomic, transcriptomic, and proteomic sta-
bility over at least 15 transplant generations in mice [54]. These
attributes can be quality controlled from inception of the model,
and in many cases, this can be done with direct comparison
with the clinically annotated tumor of origin.
Finally, unlike the vast majority of long-established human
breast cancer cell lines, a majority of PDX lines were
established from primary tumors rather than tumor cells de-
rived from pleural effusions, ascites, or other metastatic sites.
Thus, in perhaps an important way, PDX lines may serve to
complement existing cell lines rather than supplant them, de-
pending on the question(s) being asked.
3.2 To what degree do PDX models truly recapitulate
the biology of the tumor of origin in the patient,
particularly with respect to treatment response?
One of the main open questions relates to whether PDX
models retain the intra-tumoral heterogeneity of the tumor of
origin. While many PDXs appear to retain the heterogeneity
of the parental tumor of origin, loss of heterogeneity, or a
Bbottlenecking^ clonal selection upon transplantation, has
been observed in others [44]. An example of such selection
came from comparative genomic sequence analysis of a pri-
mary tumor, a patient-matched brain metastasis, and a PDX
model derived from the primary tumor [37]. As expected, the
metastatic lesion retained mutations found in the primary tu-
mor but also possessed de novo mutations and deletions not
observed in the primary tumor. Also, as expected, the PDX
derived from the primary tumor retained the primary tumor
mutations. Unexpectedly, the PDX showed the mutation spec-
trum found in the metastasis indicating that the metastatic
subclone was present within the primary tumor and that it
was this aggressive subclone that grew as a PDX. Thus, it is
critical to compare the tumor of origin with its related PDX
line as carefully as possible, whenever possible, to ensure
accurate recapitulation of as much patient/tumor biology as
possible, including tumor heterogeneity.
As recounted above, the inability to relate a cell line to its
patient of origin is one of the primary places where long-
established cell lines fall short. Thus, cell lines simply cannot
be used for this purpose. In contrast, PDX models, and the
tumors from which they were derived, have been compared
directly at multiple levels in several studies. At the histological
level, several studies have demonstrated that PDXs are virtu-
ally indistinguishable from the tumor of origin, including
H&E-stained sections, as well as by immunostaining for bio-
markers such as ER, PR, HER2, Ki67 positivity, etc. At the
genomic level, PDXs show similar genomic rearrangements,
copy number alterations, mutation profiles, and variant allele
frequencies [71–73, 99, 100], observed in the tumor of origin.
These results demonstrate not only stability of the PDX when
transplanted from one species to another but also transplant-
ability of clonal heterogeneity in many cases.
At the transcriptome level, PDXs generally show remark-
able fidelity with respect to mRNA expression profiles
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(RNAseq) [101, 73]. While proteomic comparisons between
PDXs and their respective tumors of origin have not yet been
completed, as stated previously, both transcriptomic and pro-
teomic (RPPA) expression patterns have been shown to be
remarkably stable across transplantation generations [54].
With respect to metastatic behavior, this is an open and
active area of investigation across several groups. In general,
PDXs have been shown to produce circulating tumor cells, as
well as disseminated micrometastases and macrometastases to
several distant sites ([71, 102, 54, 103] and Miragaya et al.,
unpublished). When evaluated for fidelity with the metastatic
behavior of the tumor of origin, PDXs showed comparable
metastatic site specificity ([71] and Miragaya et al., unpub-
lished). As expected, PDXmodels are generally more metasta-
tic in more immunocompromised hosts (e.g., larger metastatic
nodules in non-obese diabetic (NOD) severe combined immu-
nodeficiency disorder (SCID) gamma (NSG) mice vs. NOD/
SCID; ALW, unpublished data). This could be due to faster
tumor growth and/or more permissive colonization of the dis-
tant sites. These observations warrant further investigation to
test the generality of these initial findings and to test the degree
of influence of the immune system in the metastatic process.
3.3 What is the status of patient-PDX Bcredentialing^
for relevance of PDX models in therapeutic studies?
Among the most critical issues to be addressed is whether
PDX models respond to a given treatment in a manner similar
to the tumor of origin in the patient. If so, PDXmodels should
serve not only as relevant as experimental models but also as
valuable translational research tools, especially if ultimately
shown to have predictive value clinically. Again, this is a very
active area of investigation in several groups. However, no
Btreatment standards^ are yet available, largely due to the lack
of comparative pharmacokinetic and pharmacodynamic data
that would allow researchers to translate directly between
PDX evaluation and clinical evaluation.
In preclinical treatment studies conducted to date, PDXs
showed comparable responses to the tumor in the patient of
origin when treated with comparable therapeutic agents. An
early study evaluating seven xenografts showed an observed
concordance of response between patient tumor and corre-
sponding PDX of 71% versus a statistically expected concor-
dance of 47% [68]. However, sample size was limited for
direct comparison due to the types of treatment used clinically
(adjuvant or post-radiation chemotherapy) in this patient co-
hort that could not easily be recapitulated in mice; thus, statis-
tical significance was not quite reached using this sample size
(kappa = 0.46, P = 0.08). In a later study, a majority of xeno-
graft lines tested also showed qualitatively identical treatment
responses as the corresponding patient treated with a similar or
identical agent in the neoadjuvant (before surgery) setting, and
statistical significance was achieved using this increased
sample size [54]. Overall concordance of responses was
~92% (Ƙ = 0.75, P = 0.003), and there was a significant
association between the xenograft and patient-derived results
(Fisher exact test, P = 0.04). While both studies were
relatively small, taken together, PDXs do recapitulate tumor
responses seen clinically with good efficiency. Importantly, at
least with respect to these selected standard-of-care agents,
and under the specific conditions tested, this recapitulation
does not appear to be influenced by the immunodeficiency
of the host mice used. Thus, PDX models and associated
data should serve as useful predictors of response in patients
with at least some agents under some conditions. However,
this hypothesis remains to be tested in a rigorous manner in
both retrospective and prospective (co-)clinical trials.
3.4 Which immunocompromised mouse model should be
used formost efficient PDX generationwhile still retaining
the highest possible fidelity with the human disease?
A variety of immunocompromised, or immunodeficient,
mouse models now exist that can be used as transplantation
hosts to develop breast cancer PDX models (Tables 3 and 4).
While all mouse models listed are capable of generating PDX
models under various transplant conditions, and using various
sample types, a consensus has yet to be reached as to the
Bbest^ host to use. Thus, choice of immunocompromised host
remains largely a question of investigator preference until
rigorous head-to-head studies are conducted, and a large
enough body of data is available for multivariate analysis.
Such data need to be related not only to the various
transplantation conditions being employed but also to the
characteristics of the underlying patient populations, and
tumor types, being evaluated in order for meaningful
conclusions to be drawn.
3.4.1 Athymic nude mice
Until approximately a decade ago, the most commonly
used immunocompromised mouse model used for gener-
ation of breast cancer xenografts was the athymic Bnude^
mouse [104–106], which is homozygous for loss-of-
function mutation of the Foxn1 gene (encoding the
forkhead box N1 transcription factor) (a.k.a. nu, Hfh11)
[107, 108]. The Foxn1 gene is essential for the
development of the thymus and some ectodermal
derivatives, including hair follicles (hence the Bnude^
phenotype), and leads to loss of functional T- and B-
cells. The mice retain functional natural killer (NK) cells,
macrophages, and antigen-presenting cells (APCs).
To support growth of estrogen-dependent breast cancer cell
lines, athymic mice require supplementation with estradiol
due to low endogenous levels of circulating estrogen
[109–112]. The same appears to be true for other
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immunocompromised mice—even if they may have higher
estrogen levels, cell lines only grow when the mice are sup-
plemented with exogenous estradiol. While historical rates of
generating stable PDX lines have been relatively low using
nude mice, alternative transplantation methods (e.g., subcuta-
neous transplantation of tumor fragments into the intra-
scapular fat pad or flank) do appear to allow efficient PDX
establishment (Table 3) ([68, 113, 114], Gomez-Miragaya
et al., unpublished).
3.4.2 Rag1/Rag2 mice
Rag recombinase-deficient (Rag1 and/or Rag2) mice have
been used sporadically for xenograft studies, mainly for
generating cell line xenografts. However, these mice have
not been used extensively for attempts to generate PDX
lines (see Table 3). Like athymic nude mice, B- and T-cell
function is abrogated [115] due to loss of function of the
recombinases required for the somatic recombination of
antibody chains and mature T-cell receptors. Rag knockout
mice may be a useful alternative for some treatment response
studies using anthracycline-based or other DNA-damaging
therapies because the consequences of Rag mutations are
relatively specific to the hematopoietic system. As such,
these mice can tolerate higher levels of DNA damage than
mice carrying the SCID mutation (Prkdc, which encodes a
ubiquitous DNA repair enzyme; see below) [116].
3.4.3 SCID mice
Most of the major breakthroughs made in efficient gener-
ation of PDX lines have been made using newer, more
immunocompromised, mouse models. These include
SCID mice which carry a mutation of the protein kinase,
DNA-activated, catalytic polypeptide (Prkdc) gene
encoding a protein kinase required for somatic variable,
diversity, joining (VDJ) region recombination of antibody
chains and T-cell receptors, as well as for DNA repair.
Such mice show B- and T-ce l l de f i c i ency, bu t
background-dependent leakiness does occur. SCID mice
retain cellular immunity [117–121]. The SCID mutation
is generally used in combination with other mutations that
further cripple the immune system for xenograft work.
However, SCID mice remain prone to premature death,
Table 4 Host mouse strains used by institution
Institution Host mouse strain
abbreviation
Full strain designation Vendor Stock number
Baylor College of Medicine NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
SCID/Bg CB17.Cg-PrkdcscidLystbg-J/Crl CR 250
Bellvitge Institute for Biomedical
Research IDIBELL (Spain)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX via CR 005557
NOD/SCID NOD.CB17-Prkdcscid/J JAX via CR 001303
Nude Athymic nude—Foxn1nu Harlan/Envigo
British Columbia Cancer
Agency (Canada)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
NRG NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ JAX 007799
Ecole Polytechnique Federale
De Lausanne (Switzerland)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
Institut Bergonié (France) NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX; bred in house 005557
Institut Curie (France) Swiss Nude Crl:NU(Ico)-Foxn1nu CR
The Jackson Laboratory
(JAX) (USA)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
MD Anderson Cancer Center
(USA)—Meric-Bernstam
Nude Athymic nude—Foxn1nu MDACC Colony NA
MD Anderson Cancer Center
(USA)—Piwnica-Worms
NOD/SCID NOD.CB17-Prkdcscid/NcrCrl CR 394
University of Colorado Anschutz
Medical Campus (USA)
NOD/SCID NOD.CB17-Prkdcscid/J JAX 001303
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX; bred in house 005557
University of Manchester Institute
of Cancer Sciences (UK)
NSG NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ JAX via CR 005557
University of Michigan (USA) NSG NOD.CB17-Prkdcscid/J JAX; bred in house 005557;
NOD/SCID NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 001303
University of Utah Huntsman—
Cancer Institute (USA)
NOD/SCID NOD.CB17-Prkdcscid/J JAX 001303
Walter and Eliza Hall Institute of
Medical Research (WEHI) (Australia)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX; bred in house 005557
Washington University (USA) NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
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due in part to their high prevalence of spontaneous T-cell
lymphomas [121].
3.4.4 SCID/Beige mice
Combination of the Beige (Bg) mutation with the SCID mu-
tation has been shown to enhance the take rate of human
leukemias and other cell types, including breast cancers
[122–125, 54]. In addition to B- and T-cell deficiencies, dis-
ruption of Bg results in a lysosomal trafficking defect and
eliminates NK cell function, but leads to a ~3-fold increase
in the number of macrophages relative to the parental wild-
type mice [126, 127, 122, 123]. Macrophages are essential for
normal mammary gland development. As such, this increase
in macrophage content may be advantageous [128, 129].
Further, recent data showing promotion of tumor invasion
and metastasis by immature myeloid cells of the macrophage
lineage may account for some of the advantages of this immu-
nocompromised background [130]. Use of this genetic back-
ground allows stable take rates in excess of 20% under various
conditions, but successful transplantation in this background
is enhanced significantly by estradiol supplementation
(Table 3) [54], likely by an ER-alpha-mediated stimulation
of bone marrow-derived monocytes [54, 131].
3.4.5 NOD/SCID mice
Amajor advance for the generation of PDXmodels came after
genetic introgression of the NOD mutation into the SCID
background, which compromises cellular immunity, via im-
paired function of NK cells, APCs, and macrophage cells.
While impaired, presence of NK cells and macrophages in
athymic and NOD/SCID mice can lead to elimination of tu-
mor cells over time [132–134]. Use of this background has
allowed take rates in excess of 20% on a routine basis
(Table 3) (see [71, 135, 69, 136] and Gomez-Miragaya et al.,
unpublished; Piwnica-Worms et al., unpublished).
3.4.6 NOG and NSG mice
Development of the NOD/SCID background has continued
with the addition of IL2-receptor gamma truncation/
disruption mutations (BNOG^ or BNSG^ mice, respectively)
which compromises the mouse immune system further by
impairing cytokine signaling involved in innate cellular im-
munity [65, 137, 138]. Use of this background has been ex-
tensive across multiple groups and has allowed take rates in
excess of 20% overall to be achieved on a routine basis
(Table 3) ([69, 71, 54, 37, 139, 74, 140, 73, 141]; Gonzales-
Suarez et al., unpublished; Bult et al. unpublished). The pri-
mary distinction of the NSG and NOG strains is that the func-
tion Il2rg in NSG is completely ablated. In NOG, the Il2rg
mutation still produces a protein product that can bind to
cytokines, but there is no signaling activation. NSG mice are
less susceptible to thymic lymphomas than NOD/SCID mice
and have a longer lifespan, making them well-suited for
engrafting slower-growing human tumors.
The NSG-recipient mouse has been shown to support
greater engraftment of human hematopoietic stem cells (hu-
CD34+ cells) than some other currently available strains [137,
142]. As a consequence NSG mice can be engrafted with
functional human immune systems permitting the potential
to study primary human tumors in vivo in the presence of a
human immune system. However, NSGmice are also reported
to develop lymphocytic neoplasms occasionally from human
B- and T-cells co-transplanted with the human tumor frag-
ments, which rapidly outgrow human epithelial tumor cells
[143, 144]. Nonetheless, NSG mice are currently the most
popular choice for developing breast cancer PDX, with the
majority of the consortium groups using NSG exclusively or
in combination with other strains.
An interesting modification of the NSG is the NRG strain,
which replaces the SCID mutation with a Rag1 mutation.
These mice were used recently for the intraductal injection
approach for PDX development [141]. Evaluation of NRG
mice in experimental therapeutic studies involving DNA-
damaging agents would be of considerable interest.
3.4.7 Comparisons of immunocompromised hosts with regard
to breast cancer PDX modeling
With multiple host mouse models capable of generating PDX
lines under a variety of conditions, using a broad range of
tumor types, it is important to note that controlled head-to-
head comparisons of single-tumor fragments transplanted into
multiple immunocompromised host models under otherwise
identical transplant conditions have not been conducted exten-
sively. Thus, it is not currently possible to state definitively
that one immunocompromisedmouse model is superior to any
other for generating breast PDXs. Similarly, comparison of
take rates achieved between various groups is difficult due
to considerable differences in tumor types used for transplan-
tation (e.g., low-grade vs. high-grade primary cancers, prima-
ry tumors vs. metastatic tumors, before or after treatment) and
patient cohort characteristics (e.g., ethnically diverse or not).
Limited side-by-side comparisons of engraftment efficien-
cy have been performed, suggesting that the SCID/Bg or
NOG/NSG backgrounds may provide superior engraftment
of various types of human cells [122–125]. Indeed, when
comparing two similar cohorts of breast cancer patients, pri-
mary tumors showed equivalent take rates in either the SCID/
Bg or NSG backgrounds [54]. However, this study was not a
head-to-head comparison using exactly the same patient sam-
ple into both backgrounds simultaneously. While the range of
PDX models produced in these two backgrounds was similar,
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it remains possible that each genetic background might favor
the establishment of different types.
Some studies have now shown that positive engraftment of
breast tumors into certain mouse strains correlates with high
tumor grade or poor patient outcome [145, 71, 66, 99].
Whether the prognostic value of engraftment would extend
to more immunocompromised hosts or whether retention of
some cellular immunity in the host provides more information
regarding tumor aggressiveness in the patient is still unknown.
3.5 What is the best transplantation site?
A variety of transplantation sites are available in the mouse,
and several have been used in attempts to generate breast
cancer PDX models. Tissue can be transplanted into the ante-
rior compartment of the eye [146, 147], under the renal cap-
sule [148–151], within the intrascapular fat pad [68], subcu-
taneously (ear, flank, etc.), or orthotopically within the mam-
mary fat pad (either the intact (IFP) or epithelium-free
Bcleared^ (CFP) fat pad) [152] or injected into the mammary
ducts themselves [153, 154, 141].
In addition to these approaches for modeling primary tu-
mors, Bexperimental metastasis^ methods have been devel-
oped in which tumor cells are injected through the tail vein
or the iliac artery or by intracardiac injection, allowing estab-
lishment of tumors at other organ sites including bone, brain,
lung, and liver (e.g., [155–160] and references therein). A
bone-to-bone xenograft experimental metastasis model has
also been developed [161].
With respect to PDX model development, subcutaneous
and orthotopic transplantation sites are generally used
(Table 3), with orthotopic transplantation into the mammary
fat pad considered preferable by some as it should more close-
ly represent the human breast with respect to the microenvi-
ronment. However, the intraductal approach is also attractive
with respect to the range of orthotopic options available. For
example, in one study, cells from 16 tumors that successfully
formed primary grafts after intraductal injection failed to en-
graft at 26 subcutaneous injection sites [141], but direct com-
parison of intraductal with sophisticated extraductal grafting
techniques has not been performed.
3.6 Is it necessary to eliminate endogenous mouse
epithelium from the mammary fat pad (i.e., Bclear^ the fat
pad) for efficient orthotopic transplantation?
Elegant transplantation studies conducted nearly six decades
ago [162, 152, 163] demonstrated that the adult mammary
gland contains growth-quiescent epithelial regenerative stem
cells that are distributed throughout the entire gland. These
stem cells could be activated to self-renew upon transplanta-
tion of small duct fragments (~1000–2000 cells) into the
epithelium-free mammary fat pad of recipient mice and were
capable of regenerating a morphologically normal and func-
tional, ductal tree. However, these same fragments would not
regenerate a ductal tree in the presence of preexisting ducts in
the recipient animal. Thus, the presence of endogenous nor-
mal epithelium is inhibitory to transplanted epithelium, there-
by necessitating removal of the endogenous epithelium
(Bclearing^) for the transplant to grow.
In contrast, neoplastic tissue transplanted into an intact fat
pad will grow in the presence of endogenous normal epitheli-
um. However, this ability does not necessarily mean that in-
hibitory signals do not exist, only that neoplastic tissue is
capable of overcoming them, or is unresponsive to them,
should they exist. Thus, while neoplastic tissue may be able
to overgrow normal epithelium, removal of whatever inhibi-
tory influences may exist might allow neoplastic tissue to
grow even better. Conversely, it is formally possible that nor-
mal epithelium could promote growth of neoplastic tissue.
These alternative hypotheses have not been tested in a con-
trolled manner.
From inspection of Table 3, use of the intact mammary fat
pad (IFP) does not appear to interfere with effective transplan-
tation of primary tumor tissue. In fact, there are preliminary
indications that the IFP may be superior to the CFP for trans-
plantation of both fresh and previously cryopreserved tumor
tissue (Table 3). That said, the continued presence of endoge-
nous mouse epithelium may complicate some downstream
molecular analyses (e.g., transcriptome arrays, reverse phase
protein arrays (RPPAs), etc.), and so use of the IFP may not be
desirable in all instances.
3.7 Is estradiol supplementation necessary? If so, what is
the most effective way to deliver it?
With the possible exception of metastatic ER+ breast cancer, it
has proven difficult to establish PDX models of primary, par-
ticularly lower-grade, ER+ luminal A tumors. Further, once
established, ER expression can be lost over the course of pas-
saging from mouse to mouse (e.g., [68, 57, 164], Gomez-
Miragaya et al. unpublished), though many current studies
have not shown this behavior. These difficulties are offset, in
part, by the fact that ER+ cancers account for approximately
75% of all breast cancers, thus offering more opportunities to
make successful PDX models.
In attempts to increase the take rate of ER+ tumors, various
forms of estradiol supplementation have been used, ranging
from commercially prepared slow-release plastic pellets (e.g.,
Innovative Research) to hormone-loaded silastic tubes, or
beeswax pellets. To date, progesterone supplementation, ei-
ther alone or in combination with estradiol, has not been eval-
uated. Unfortunately, in addition to significant urinary tract
complications associated with the use of estradiol-containing
implants of all sorts, a major issue with this approach is that
the implant becomes depleted of hormone over time, requiring
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periodic replacement if hormone levels are to be maintained
long-term. To address these issues, several groups have
revisited use of an old method by testing the ability of
estradiol-supplemented drinking water for its ability to sup-
port PDX growth with promising results (Table 3) (see [68,
165–168, 136]; Lewis et al., unpublished). Given the signifi-
cant limitations of delivery using implants, estradiol-
supplemented drinking water may be a superior method of
delivery. However, it remains unclear whether rates of PDX
establishment will be comparable to those using other delivery
methods.
While most groups engaged in PDX generation use some
form of estradiol supplementation for ER+ tumors, use of
supplementation is not always used when transplanting ER−
tumors (Table 3) [71, 114, 113]—the reasoning for not using
supplementation being that ER− tumors should not require
estradiol supplementation for their growth. However, compar-
ison of stable take rates of primary cancers from statistically
similar cohorts in the SCID/Bg host strain, with and without
supplementation with slow-release estradiol pellets, demon-
strated that supplementation increased the stable take rate al-
most 10-fold, from 2.6% without supplementation (only a
single TNBC PDXs generated from 38 patients attempted)
to 21% with supplementation (15 PDXs representing multiple
IHC subtypes from 70 patients attempted) in this host back-
ground [54]. These data indicating a requirement for estradiol
supplementation were consistent with previous studies show-
ing that estradiol supplementation stimulates growth of breast
cancer xenografts, including ER-negative xenografts [71, 169,
170, 69]. Subsequently, the stimulatory effect of estradiol sup-
plementation on ER-negative tumor was investigated specifi-
cally and shown to be due, in part, to an effect on bone
marrow-derived myeloid cells that promote angiogenesis
and tumor growth that was dependent on ERα [131, 171].
Of potential significance, several groups have successfully
used NSG mice without estradiol supplementation (Table 3),
suggesting that unlike SCID/Bg, successful transplantation in
NSG animals may not require supplementation. However,
there may be significant differences in the patient cohorts
and tumor characteristics from one group to another that
may contribute to this apparent difference. That said, the
intraductal approach appears to also one to grow ER+ cell
lines and PDXs in the absence of endogenous hormones
[154, 141].
It will be critical to address these potential host background
differences going forward.
3.8 How can lower-grade tumors, ductal carcinoma in situ,
and normal tissue be grown with higher efficiency?
While it has been comparatively easy to establish PDX
models from metastatic sources such as ascites and pleural
fluid, as well as from high-grade, more aggressive primary
tumors from the breast itself (Table 3), it has proven relatively
difficult to establish PDXs from grade I/II tumors, ductal car-
cinoma in situ (DCIS), and normal breast epithelium [153, 75,
54, 66, 70, 114, 113].
One possible explanation for elevated take rates in high-
grade primary tumors could be a higher frequency of tumor-
initiating cells (TICs) (a.k.a. cancer stem cells) relative to
lower-grade tumors [172, 173]. In one study, the frequency
of cells expressing aldehyde dehydrogenase 1 (ALDH1), a
marker associated with TIC properties in some, but not all,
breast cancers, predicted the rate of engraftment as a PDX.
The general hypothesis is that the higher the proportion of
TIC, the higher the likelihood of successful transplant. This
hypothesis makes intuitive sense from a statistical standpoint.
However, if this were the entire explanation for differential
take rates, transplantation of larger fragments of lower-grade
tumors should address the problem of low take rates because
more TIC would be present in the transplant. Given the wide-
spread failure of several investigators to establish lower-grade
tumors under a variety of conditions, this explanation, while
plausible, is not likely to account entirely for the elevated take
rate in high-grade cancers.
One other plausible explanation for differential take rates of
low-grade (including DCIS) versus high-grade cancers is that
immunocompromised mouse hosts do not express one or
more factors that low-grade tumors require for growth in
mice—factors that at least some higher-grade tumors do not
require (analogous to a shift from hormone-dependent to
hormone-independent tumor growth in some ER+ breast
cancers).
In addition to this potential contribution of tumor evolu-
tion/progression, there are several known incompatibilities
between human and mouse ligand/receptor pairs that may
interfere with the ability to transplant human tumors into mice
efficiently. For example, several mouse ligands (e.g., prolac-
tin, hepatocyte growth factor (HGF), interleukin-6 (IL-6)) do
not activate their human receptor counterparts [174–176].
Thus, tissue-appropriate expression of one or more of these
human ligands either as transgenes or as knock-in constructs,
in an immunocompromised mouse background, may be nec-
essary to stimulate growth of lower-grade tumors.
One technical modification that may help with growth of
lower-grade tumors is the use of Matrigel or similar basement
membrane extract preparation in the transplantation process.
Head-to-head comparisons of take rates with and without
Matrigel using otherwise identical host mice and tissue
sources have not been conducted. That said, a comparatively
high take rate of 37% (10 of 27 patients) was achieved [69]
using primary tumor fragments or metastatic cells (pleural
fluid/ascites) coated in Matrigel and implanted into the intact
fat pad of either estradiol-supplemented NOD/SCID or NSG
mice. However, this reported take rate appears to have been
attenuated with additional patient samples attempted
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(Table 3). There also may be some indication that the use of
Matrigel in the context of the IFP may help somewhat
(Table 3). However, using previously cryopreserved tissue,
the addition of Matrigel under otherwise identical transplant
conditions does not appear to enhance the take rate (Table 3).
Another promising approach is the use of intraductal injec-
tion of cells. This method has been used to grow DCIS [153],
ER+, and HER2+ breast cancer [154] and molecular apocrine
cancers [141], with excellent recapitulation of the biology of
the source tissue. The intraductal approach may allow human
epithelium to interact with normal epithelium in much the
same way that it would in a patient, thereby perhaps allowing
growth whereas isolated fragments of human tissue may not
grow in the absence of such interactions.
3.8.1 Progress toward development of mouse models
of human breast premalignant lesions
For a comprehensive review of human DCIS models includ-
ing in vitro models, please refer to Kaur et al. [177].
Efforts toward developing models of premalignant breast
lesions go back to 1975 when Outzen and Custer reported
transplantation of small fragments of human Bcystic
hyperplasias^ into cleared mammary fat pads of nude mice
and the lesions were maintained for 2–3 months [178]. The
hyperplastic lesions proliferated in mice and recapitulated the
histologic patterns of the original patient biopsy specimens
[60]. Other investigators also reported that fragments from
human breast atypical hyperplasias could be maintained for
up to ~6 months in nude mice and, sometimes, the lesions
would dedifferentiate, meaning that they potentially
progressed by forming disorganized epithelial hyperplasias.
Three transplantation sites were used, cleared mammary fat
pad, subcutaneous, and intraperitoneal. The cleared mammary
fat pad site was reported to result in the highest take rate
(reviewed in [178]). Later, a study in 1997 reported transplan-
tation of fragments from 25 cases of human ductal carcinoma
in situ (DCIS) in the back of athymic nude mice [179].
Fragments were recovered 2–8 weeks after transplantation
and maintained their DCIS components in 93% of transplants
[179]. The purpose of this study was to analyze ER expression
in the transplanted DCIS and to assess their response to estro-
gen supplementation. However, the authors reported no ex-
pansion in response to hormonal supplementation during the
8-week follow-up. In a more recent study, human DCIS tissue
fragments were implanted subcutaneously in athymic nude
mice in order to study the therapeutic efficacy of a
farnesyltransferase inhibitor. The DCIS xenografts were main-
tained for up to 21 days and showed a take rate of about 66%
[180]. Recently, Espina et al. demonstrated successful xeno-
transplantation of freshly procured DCIS organoids and
in vitro propagated spheroids derived from patient DCIS bi-
opsy or surgical specimens. This group reported that tumors
formed in mice at a rate of ~80% (21/27 cases transplanted)
from either freshly procured organoids from DCIS of any
grade or propagated DCIS organoids passaged in vitro for
2–12 months.
Toward the development of cell lines that would mimic the
histologic and molecular features of premalignant breast le-
sions in xenografts, Miller and colleagues developed
MCF10ATcell line models. Xenografted lesions derived from
MCF10AT cells generated the full spectrum of human breast
lesions including normal ducts, hyperplasia, atypical hyper-
plasia, carcinoma in situ, and invasive cancers [181, 182]. A
clonal derivative of a tumorigenic variant of MCF10AT xeno-
grafts, MCF10DCIS.com, produced comedo DCIS when
transplanted at early passages into cleared fat pads of
immunodeficient mice. Subcutaneous injection of MCF10
DCIS.com into nude mice resulted in rapidly growing
lesions that were predominantly comedo (a more aggressive
type of DCIS with central necrosis) [178]. When transplanted
subcutaneously, the MCF10DCIS.com lesions appeared in
about 3 weeks and were composed of luminal epithelial cells
surrounded by both a myoepithelial cell layer and a basement
membrane. Some areas of early lesions progressed to invasive
cancers in about 5 to 6 weeks [183]. Another premalignant
cell line model SUM225CWN was derived from a chest wall
recurrence of a ductal carcinoma lesion [184]. Similar to those
of MCF10DCIS.com, xenografts of the SUM225CWN cell
line form DCIS-like lesions in NOD-SCID mice in as early
as 2 weeks [185].
With the idea that human DCIS initiates inside the ducts,
Behbod et al. utilized the intraductal transplantation technique
[153]. This approach, referred to as mouse-intraductal
(MIND), involves injection of epithelial cells derived from
DCIS patient samples or cell lines directly into the immuno-
compromised mouse mammary ducts. This is the first model
to capture the natural evolution of human DCIS in mice since,
similar to humans, the cancer cells initially form in situ lesions
inside the mammary ducts followed by invasion as they by-
pass the natural barriers of the ductal myoepithelial cell layer
and the basement membrane. Initially, MCF10DCIS.com and
SUM225CWN cells as well as one case of primary human
DCIS were utilized. The DCIS-like lesions generated from
the MCF10DCIS.com (DCIS.com) and SUM225CWN cell
lines formed DCIS-like lesions as early as 2 weeks and slowly
progressed to invasive lesions in 10–14 weeks [153]. Later, in
2011, this group reported reproducible growth and expansion
of epithelial cells derived from patient DCIS biopsy and/or
surgical samples as well as hyperplasias in NOD-SCID IL2r
mice by the MIND method. The xenografted DCIS-like le-
sions and hyperplasias expressed similar biomarkers (ER, PR,
and Her-2) as the original patient samples. The DCIS-like
lesions generated by the primary DCIS cells in MIND models
formed in situ lesions as early as 8 weeks, and a fraction of
those slowly progressed to invasive lesions in 6–12 months
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following transplantation (Behbod, unpublished results).
The take rate for primary DCIS MIND models is ~50%.
A key difference of the MIND method is that pure epithe-
lial cells are injected intraductally as opposed to previous
methods that transplanted organoids or pieces of tissues in
the cleared mammary fat pads of immunocompromised
mice.
3.9 Can Bhumanization^ of immunocompromised mice
enhance take rate and improve translational relevance?
There are currently two different classes of Bhumanization^
methods that are being explored for their ability to enhance
PDX growth and perhaps provide a more biologically similar
environment as in the tumor of origin.
3.9.1 BHumanization^ of the mammary fat pad
A few groups have attempted to increase the efficiency of
primary tissue transplantation by Bhumanizing^ the mammary
fat pad of mice with the introduction of an immortalized hu-
man fibroblast cell line into the mammary fat pad prior to
xenograft transplantation [75, 87, 186]. Use of this methodol-
ogy allowed organotypic growth of normal human mammary
epithelium and appears to allow PDX establishment under
some circumstances (Table 3). However, Zhang et al. [54]
showed that provision of immortalized fibroblasts attenuated
take rates considerably using statistically comparable cohorts
in the SCID/Bg background reducing the rate from 21.4 to
3.4% under otherwise identical transplantation conditions.
Thus, it remains unclear whether immortalized fibroblasts en-
hance PDX take rates.
Aside from immortalized fibroblasts, it is also possible that
co-transplantation of mesenchymal stem cells may enhance
PDX take rates. These cells were shown to enhance
mammosphere formation in vitro [187, 188] and to stimulate
growth and metastasis of established xenografts in vivo [71,
189, 190, 175]. However, this approach has not yet been tested
extensively.
3.9.2 BHumanization^ by reconstitution of the human immune
system in immunocompromised mice
A disadvantage of any xenograft as a model for human cancer
is growth of the tumors in immunocompromised mice, which
is required in order to avoid rejection of the tumor by the host
mouse immune system. Lack of normal immunity in tumor
xenografts is an important caveat, given the well-established,
multiple roles of the immune system in tumor initiation and
growth, metastasis, and response to therapy. In most patients,
tumors arise in the presence of a functional immune system,
and the tumor evolves to evade immune rejection under selec-
tive pressure [191]. Once a tumor is detectable, it has already
avoided immune-mediated rejection, and thereafter, the im-
mune system actually plays a paradoxical role in promoting
tumor progression and metastasis [192–194]. For example,
macrophages can assist with tumor cell intravasation to facil-
itate tumor dissemination [195]. Myeloid-derived suppressor
cells can promote angiogenesis and suppress adaptive im-
mune responses [196], and regulatory T-cells reinforce the
immunosuppressive tumor microenvironment [197].
On the fother hand, it has been clear for a number of
years that the immune system can, in some cases, be suc-
cessfully stimulated to eradicate tumors. Indeed, recent ad-
vances in immunotherapy using immune checkpoint inhib-
itors have led to exciting therapeutic results in certain can-
cers [198, 199]. The immune system is also instrumental in
sustaining tumor regression upon oncogene inactivation
[200], which is highly relevant when considering therapeu-
tic effects. Therefore, incorporation of a functional or par-
tially functional human immune system into xenograft
models might more accurately model human breast cancer
growth, metastasis, and response to therapy, particularly
those known to involve an immune system function in their
mechanism of action.
Generation of mice with reconstituted human immune sys-
tems was first accomplished in 1988 [201] and is now com-
monly used to study human blood cell development and dis-
eases of the hematopoietic system [65]. The idea of usingmice
with Bhumanized^ immune systems to study human cancer is
not new, but until recently has been mostly focused on tumors
of the hematopoietic lineage. Immune humanization in mice
carrying human breast cancers is now feasible [202], with two
key stipulations: (1) the mouse host has to be appropriate for
growth and development of human tumor cells and human
immune cells and (2) the immune system must not recognize
the tumor as foreign and reject it (graft vs. tumor reaction).
State-of-the-art strategies, as well as caveats, have been re-
cently reviewed elsewhere [203–206].
In summary, it has become clear that the Btumor cell-
centric^ approach to breast cancer therapy may not be suffi-
cient to eradicate the disease, and a dual approach targeting
both the tumor and its specialized microenvironment might be
more effective [207]. Many promising therapies for breast
cancer rely on an effective anti-tumor immune response,
and they need to be tested preclinically in animal models
before entering trials. Examples include vaccines for breast
cancer prevention or inhibiting outgrowth of occult metas-
tasis [208], drugs to prevent macrophage recruitment into
tumors where they promote metastasis [209], or new im-
mune checkpoint inhibitor combinations [210]. In all
cases, a better understanding of human tumor-immune in-
teractions is needed. Future development of PDX models
in mice with matched, functioning human immune systems
may hold potential to advance breast cancer research and
lead to new treatments.
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3.10 What do we need to do to make PDX repositories
truly clinically relevant? Toward development of data
standards for Bclinical^ annotation of patient breast
cancer samples and their associated PDX models
As a newly formed international consortium, we herein report
details of a large collection of breast cancer PDX models that
recapitulate patient biology to a high degree. However, the
patient-related clinical data and PDX-related data collected
by each individual group vary significantly, both in terms of
content and terminology used. This review therefore provides
an opportunity to begin a discussion about development of an
international data standard that can be adopted by all PDX-
generating groups to allow direct comparison of collections
worldwide and provide the foundation for larger-scale inter-
national, multi-institutional collaborations. Ideally, data ele-
ments used should integrate well with existing data reposito-
ries and portals such as GEO, Oncomine, cBioPortal, etc., by
having a shared conceptual understanding and similar termi-
nology that allows direct mapping of data elements between
PDX resources and data portals. Significant progress has been
made in this area, including community discussions about
standards for data format and content that will enhance data
sharing and integration, which will be discussed in detail at a
later date.
There are two broad classes of data that can be collected:
patient-centric clinical data about the patient and tumor of origin
and PDX-centric data about the characteristics of the xenografts
themselves. Within these two broad classes, the amount of data
that can potentially be collected is relatively large, while the
ability to collect detailed data may be limited by personnel avail-
ability and financial support. In particular, with patient privacy
laws in effect in various countries, care must be taken to firewall
personally identifiable health information from other data that
can be shared publicly without concern that privacy will be com-
promised. To accomplish this division requires dedicated
Bclinical^ personnel with clearance to access and abstract clinical
data and an independent group of dedicated BPDX^ personnel
with access to the abstracted clinical data, as well as PDX-based
data elements and datasets. Finally, both of these efforts require
significant involvement of bioinformatics and software develop-
ment expertise for proper integration.
Clinical data can be collected with varying degrees of
ease and can be divided into what might be considered a
Bminimal^ or Bessential^ data set and a more expanded
Bideal^ data set at both the patient level and the sample
level. At the patient level, it is essential that one knows the
gender of the donor, the clinical event point that defines the
sample type(s) that have been collected from the patient for
use in PDX generation (e.g., benign/normal, primary tumor,
second primary tumor, local regional recurrence, distant
metastasis, unknown) and pathological stage (including
nodal status, etc.).
In addition to these minimal data, there are several other
data elements that greatly increase the utility of a renewable
tissue resource for use in translational studies and drug evalu-
ation. These include patient age at each clinical event point
(e.g., biopsy, surgery at which time the sample used for gen-
erating a PDX was taken), parity history, race, ethnicity, fam-
ily history of cancers, vital status and date of recording, and
any sites of distant metastasis. These data would ideally also
include treatments received by the patient, the timing of treat-
ment relative to the time of tissue collection for the production
of PDX models, and the treatment response of the tumor of
origin (most easily evaluated in the neoadjuvant setting).
At the sample level, minimal data include pathological di-
agnosis of the sample taken, hormone receptor status (ER/PR)
and percentage of positivity, HER2 status, and germline
BRCA1/2 mutation status of the tumor of origin for the
resulting PDX lines to be maximally useful. Additional data
of interest related to the sample used for PDX generation
include Ki67 labeling index, status of commonly mutated
genes like TP53 and PIK3CA, pathologic stage and grade,
molecular subtype (by multiple means), and treatment status
at the time of collection. Short tandem repeat (STR) analysis is
also essential, whenever possible, to ensure accurate patient/
PDX relationships. Given the recent reports of selective out-
growth of Epstein-Barr virus-positive human lymphomas in
attempts to generate solid tumor PDX models [143, 144], it is
imperative that each PDX model be validated appropriately
with cytokeratin and CD45 immunohistochemical staining.
Because the PDX itself is a renewable sample type, tissue is
not limiting. Thus, the PDX can be characterized to a high
degree without concern of exhausting the tissue, although
maintaining low passage lines is a clear priority. Key PDX-
based data types are essentially identical with sample-level
data types collected clinically. Namely, it is critical to confirm
the ER/PR/HER2 status in the PDX at different passages and
to conduct STR analysis to establish the unique identity of the
PDX line and to establish the direct patient/PDX relationship
whenever possible, as well as for downstream quality control
measures to ensure PDX identity and integrity over what are
likely to be decades of passage in the future.
In addition to these minimal data, other data that are useful
are PDX growth rates (doubling time), metastatic frequency
(CTC, lung, liver, bone, lymph node, brain, etc.), and any
number of B-omics^ characterizations. The -omics character-
izations possible to generate include, but are not limited to,
genomic copy number alterations, mutation status in various
genes (whole genome sequencing, exome sequencing,
Sequenom, SNP analysis, etc.), methylome, gene expression
at both the RNA level (RNAseq, array-based, QPCR, etc.) and
the protein level (reverse phase protein array, mass spectrom-
etry, Western blot, CyTOF), and metabolome (mass spectrom-
etry-based), among other possibilities. All data can then be
correlated to any subsequent behavior or response that a given
Cancer Metastasis Rev (2016) 35:547–573 563
PDX, or set of PDX models, may have to experimental ma-
nipulation. Such correlations should be particularly important
for evaluation of drug treatment responses (any number of
agents, but specifically standard-of-care agents). To be partic-
ularly powerful, PDX-based -omics characterizations should
be matched to the corresponding data derived from the tumor
of origin whenever possible. However, given that patient sam-
ples are typically limited by size, this is not always possible.
4 Summary of strengths and limitations of PDX
models for translational research and drug
development
PDX models are potentially important tools for identifying
mechanisms of de novo and acquired drug resistance, for iden-
tifying new biomarkers of breast cancer biology, for driving
drug discovery, and for evaluation of new experimental ther-
apeutics. Although superior to cell lines in recapitulating tu-
mor heterogeneity, PDX models are also biased toward more
aggressive tumors and the rate of engraftment can be an inde-
pendent predictor of patient outcome. While the majority of
PDX models represent TNBC, there has been substantial im-
provement in establishing HER2+ and ER+ luminal B tumors.
As predicted, more differentiated ER+ tumors with a lowKi67
staining index are very difficult to engraft, and in cases where
they do engraft, it is likely that selection for the most undif-
ferentiated components of the tumor has occurred, resulting in
a tumor quite different from that in the original patient. Thus,
rates of engraftment are skewed toward the most undifferen-
tiated subtypes of breast cancer and do not fully encompass
inter-tumor heterogeneity.
The recent findings that the clonal dynamics of tumors are
highly variable, ranging from minor changes on engraftment
to extensive changes that accompany selection for a minor
clone of originating cells, add a further degree of complexity
[44]. Nevertheless, polyclonality is generally well-represented
by breast xenografts, and they continue to serve as useful
models provided their clonal repertoire is taken into consider-
ation. Although metastatic lesions demonstrate improved take
rates and growth, they cannot be used to study the process of
metastasis from naïve tumors.
One of the major limitations of the PDX model is the defi-
ciency of the mouse host immune system and selectively in-
appropriate microenvironmental influences. Severely immu-
nodeficient hosts must necessarily be utilized, but these inev-
itably alter the growth kinetics of many PDX tumors and
preclude evaluation of immune-modulatory therapies. The
NSG mice are currently the most widely used strain, but these
lack natural killer, B-, and T-lymphoid cells. Humanization of
the immune system could in theory be achieved bymobilizing
peripheral blood stem cells from the same patient, although
this remains challenging on more than one front. Other
options include humanization of the mouse immune system
by co-engraftment of human bone marrow cells [211].
In addition to immune system deficiency, PDXmodels lack
human stromal components such as the different fibroblast
populations, endothelial cells, and adipocytes, being replaced
by their mouse counterparts which do not necessarily function
identically. The growth factors and stromal requirements nec-
essary for effective engraftment are poorly understood, and
human fibroblasts are rapidly out-competed by mouse stromal
cells following transplantation [71]. Genetic targeting of mul-
tiple human cytokine genes into their respective loci within
mice [212] might improve tumor engraftment through the
provision of crucial stroma-derived species-specific cyto-
kines. In addition, one might expect that co-engraftment of
mesenchymal stem cells or cancer-associated fibroblasts could
enhance tumor growth and stabilize tumor heterogeneity.
Despite these ideas, the key to fully efficient tumor engraft-
ment is not still known.
PDX models have been shown to recapitulate the drug
sensitivity responses observed in the tumors of patients, from
which they were derived. However, the implementation of
PDX mice as BAvatar models^ to guide clinical decisions will
require significant advances in this area, including rigorous
comparison of pharmacokinetics and pharmacodynamics for
various agents that will allow Bpreclinical trials^ in PDX-
bearing mice to be as comparable as possible to clinical trials
as conducted with patients. Aside from the limitations owing
to lack of a human immune or stromal system, one of the
limiting issues is the time-scale required to establish PDX
models for drug testing. We also need to collect data about
adverse drug reactions in different mouse strains.
Furthermore, not all patient tumors engraft, adding a level of
unpredictability. In order for PDXs to be relevant to the indi-
vidual patient, the engraftment rate and time required for en-
graftment need to be dramatically optimized and standardized,
without compromising the biological properties of the original
patient tumor.
At this stage in their credentialing, PDX models best serve
as basic and translational research tools, where they can have
considerable impact. One of the best examples has been seen
in the case of colorectal cancer, where PDX studies showed
that tumors with a mutated KRAS gene were not responsive to
cetuximab [213], closely mimicking that seen in large clinical
trials. These results provide compelling support for PDX
models as predictors of clinical response, and their further
implementation could circumvent long-term, costly clinical
trials in the future [214].
5 Focus for the future
At some point, perhaps even very soon, the more aggressive
forms of breast cancer will be represented well enough in the
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PDX community that it is no longer necessary to expend ad-
ditional resources and effort to develop new PDX lines to
represent them. Rather, it may be more fruitful to redirect
resources to generate PDX lines for underrepresented tumor
types or patient populations. These underrepresented tumor
types and populations may offer insights into breast disease
that would not be found otherwise and would likely facilitate
development of personalized medicine strategies.
It has already been mentioned that ER+ luminal A
and HER2+ tumors, grade I/II tumors, DCIS, and hy-
perplasias are significantly underrepresented in the PDX
collections reported herein, but the increased use of the
intraductal approach may remedy this situation.
Similarly, there are very few claudin-low or metaplastic
tumors present in the current collection; these are tu-
mors with very poor prognosis and limited treatment
options. As such, focused effort to establish PDX
models representing these underrepresented tumor types
may be preferable to the broader efforts currently
underway.
In addition to these more familiar tumor types, there are
other classes of tumors that are also underrepresented, on
which focused attention might be warranted. For example,
while some models do exist, tumors from Hispanic, African
American, Asian, and Native American and other indigenous
peoples are still underrepresented. Similarly, while males do
develop breast cancers, there are presently no male breast
cancers represented in the PDX collections presented herein.
Finally, if the proper infrastructure were developed, we have
the opportunity to try to generate PDX models from areas of
the world in which health care is limited, and PDX generation
efforts are entirely lacking. Together, these rare and underrep-
resented PDX models may provide unexpected insights that
cannot be foreseen.
6 Conclusions
1. PDX models representing clinically relevant subtypes of
breast cancer are available as phenotypically stable, re-
newable tissue lines.
2. Breast cancer PDXs recapitulate many key aspects of the
biology of the tumor of origin and therefore may serve as
excellent models for translational research.
Key unanswered questions
1. To what extent can PDX models be used as patient
Bavatars^ in preclinical evaluation of experimental
therapeutics?
2. Can PDX-based B-omics^ studies be used to develop pre-
dictive signatures and to identify key resistance
mechanisms?
3. Under what circumstances does the lack of an intact im-
mune system influence the usefulness of PDX models,
and can this be overcome?
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